MiddleBrook Pharmaceuticals Announces Changes to Management Team
October 07 2008 - 8:00AM
PR Newswire (US)
GERMANTOWN, Md., Oct. 7 /PRNewswire-FirstCall/ -- MiddleBrook
Pharmaceuticals, Inc. (NASDAQ:MBRK), a pharmaceutical company
focused on developing and commercializing novel anti-infective
products, today announced new management team members. John
Thievon, MiddleBrook president and CEO, said, "These changes are an
important first step toward transitioning MiddleBrook to a
full-fledged commercial operation. Next, we will fill key sales
management positions and begin recruiting field force
representatives. We look forward to sharing more information on our
plans and progress during our third quarter earnings conference
call." -- Timothy L. Miller has joined MiddleBrook Pharmaceuticals
as Senior Vice President, Sales Operations & Administration.
Prior to joining MiddleBrook, Miller served as Vice President,
Sales Operations & Training at Adams Respiratory Therapeutics,
Inc. (Adams). Previously, he held numerous key positions in sales,
operations and finance at Aventis Pharmaceuticals, Inc. and its
legacy companies. -- Brian J. Carlino has joined MiddleBrook
Pharmaceuticals as Vice President, Sales. Prior to joining
MiddleBrook, Carlino held multiple sales, trade, and managed care
leadership roles at Salix Pharmaceuticals, Inc. and its predecessor
company, InKine Pharmaceutical Company, Inc. Previously, he was a
sales manager at Adams Laboratories, Inc. and worked in sales at
UCB Pharma, Inc. -- William G. Volz has joined MiddleBrook
Pharmaceuticals as Vice President, Marketing. Prior to joining
MiddleBrook, Volz was Senior Director of Sales & Marketing at
Ivax Laboratories, Inc. Previously, he held successive leadership
roles in the ophthalmic division of Novartis, including Executive
Director, U.S. Sales; Global Marketing Director, Allergy; U.S.
Marketing Director, Allergy & OTC. The Company also announced
key hires in legal, information technology, finance, and investor
relations. MiddleBrook EVP and CFO David Becker said, "These
changes to our leadership team will enable us to effectively
support commercial operations and identify and implement programs
focused on extracting maximum value from company-wide resources."
-- Brad Cole has joined MiddleBrook Pharmaceuticals as Senior Vice
President, General Counsel. Prior to joining MiddleBrook, Cole
served as Associate General Counsel at Adams. Prior to Adams, Cole
was with the law firm Holland & Knight LLP, where he worked on
corporate, securities and M&A matters. -- Michael J. Butrico
has joined MiddleBrook Pharmaceuticals as Vice President of
Information Technology and Automation. Prior to joining
MiddleBrook, Butrico served as Executive Director, Information
Technology at Adams. Previously, he held key technology positions
at Chubb and AT&T. -- David N. Carlson has joined MiddleBrook
Pharmaceuticals as Vice President of Finance & Treasurer. Prior
to joining MiddleBrook, Carlson held several key finance positions
at Adams; most recently Vice President of Finance & Plant
Controller. Formerly, he held various positions in finance at
RxAmerica, a fully-integrated retail and mail service provider of
pharmacy benefit management services. -- Cynthia C. Tirpak has
joined MiddleBrook Pharmaceuticals as Vice President, Controller.
Prior to joining MiddleBrook, Tirpak was Executive Director,
Business Development & Assistant Treasurer at Adams.
Previously, she was Assistant Controller for Adams. Tirpak also
held various operational and corporate finance positions at Biovail
Pharmaceuticals and Pharmacia Corporation. She began her career as
an auditor with Deloitte & Touche and is a CPA. -- Faith
Pomeroy-Ward has joined MiddleBrook Pharmaceuticals as Executive
Director, Investor Relations & Corporate Communications. Prior
to joining MiddleBrook, Pomeroy-Ward worked in public affairs and
communications for Verizon Telecom. Previously, she served as
Senior Manager, Investor Relations & Corporate Communications
at Adams. MiddleBrook Pharmaceuticals Reports Inducement Grants
Under NASDAQ Marketplace Rule 4350 MiddleBrook Pharmaceuticals also
announced today that on Oct. 1, 2008, it granted options to
purchase 125,000 shares of MiddleBrook's common stock to two new
employees as a material inducement for them to join the company.
The options were granted pursuant to NASDAQ Marketplace Rule
4350(i)(1)(A)(iv) and under MiddleBrook's New Hire Stock Incentive
Plan, which was approved by MiddleBrook's Board of Directors on
Sept. 26, 2008. The options have a per share exercise price equal
to the closing price of MiddleBrook's common stock on the Nasdaq
Global Market on the day immediately preceding the grant date, a
ten-year term and vesting over four years, with 25 percent of the
options vesting one year from the grant date and 1/48th of the
options vesting monthly thereafter. The options have a grant date
of Oct. 1, 2008. About MOXATAG(TM): MOXATAG(TM) (amoxicillin
extended-release) tablets are a once-a-day extended-release
formulation of amoxicillin for oral administration consisting of
three components: one immediate-release component and two
delayed-release components. The three components are combined in a
specific ratio to prolong the release of amoxicillin from
MOXATAG(TM) compared to immediate-release amoxicillin. MOXATAG(TM)
is intended to provide a lower treatment dose, once- daily
alternative to currently approved penicillin and amoxicillin
regimens for the treatment of adults and pediatric patients 12
years and older with tonsillitis and/or pharyngitis. About
Middlebrook Pharmaceuticals: MiddleBrook Pharmaceuticals, Inc.
(NASDAQ:MBRK) is a pharmaceutical company focused on the
development and commercialization of anti-infective drug products
that fulfill substantial unmet medical needs in the treatment of
infectious disease. The Company is developing anti-infective drugs
based on its novel biological finding that bacteria exposed to
antibiotics in pulses are killed more efficiently and effectively
than those under standard treatment regimens. Based on this
finding, MiddleBrook has developed a proprietary, once-a-day
pulsatile delivery technology called PULSYS(R). The Company
currently markets the Keflex(R) brand of cephalexin and has
received regulatory approval for MOXATAG(TM) -- the first and only
once-daily amoxicillin product approved for marketing in the U.S.
For more on MiddleBrook, please visit
http://www.middlebrookpharma.com/. This announcement contains
forward-looking statements, within the meaning of the Securities
Exchange Act of 1934 and the Securities Act of 1933, that involve
risks and uncertainties. In some cases, forward-looking statements
are identified by words such as "believe," "anticipate," "expect,"
"intend," "plan," "will," "may" and similar expressions. You should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this announcement. All of these
forward-looking statements are based on information available to us
at this time, and we assume no obligation to update any of these
statements. Actual results could differ from those projected in
these forward-looking statements as a result of many factors,
including those identified in the sections titled "Risk Factors,"
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" and elsewhere in our Annual Report on Form
10-K for the year ended Dec. 31, 2007. We urge you to review and
consider the various disclosures made by us from time to time in
our filings with the Securities and Exchange Commission, that
attempt to advise you of the risks and factors that may affect our
future results. DATASOURCE: MiddleBrook Pharmaceuticals, Inc.
CONTACT: Faith Pomeroy-Ward, Executive Director, Investor Relations
& Corporate Communications of MiddleBrook Pharmaceuticals,
Inc., +1-301-944-6585, Web site: http://www.middlebrookpharma.com/
Copyright
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Aug 2023 to Aug 2024